 Nida Awadallah
Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Family Practice | 3 | 2021 | 426 | 1.110 |
Why?
| | Internship and Residency | 3 | 2022 | 920 | 0.940 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 366 | 0.770 |
Why?
| | General Surgery | 1 | 2022 | 125 | 0.730 |
Why?
| | Chronic Pain | 2 | 2022 | 208 | 0.730 |
Why?
| | Mentoring | 1 | 2022 | 99 | 0.710 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2008 | 209 | 0.490 |
Why?
| | Physicians | 1 | 2020 | 765 | 0.390 |
Why?
| | Curriculum | 3 | 2022 | 813 | 0.380 |
Why?
| | Pancreatic Neoplasms | 2 | 2008 | 721 | 0.370 |
Why?
| | B7-1 Antigen | 1 | 2008 | 53 | 0.300 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2008 | 31 | 0.300 |
Why?
| | Pain Management | 2 | 2022 | 285 | 0.290 |
Why?
| | Bile Ducts | 1 | 2006 | 68 | 0.250 |
Why?
| | Cholangitis, Sclerosing | 1 | 2006 | 66 | 0.240 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 445 | 0.230 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 180 | 0.220 |
Why?
| | Biomarkers, Tumor | 1 | 2008 | 1032 | 0.190 |
Why?
| | Delphi Technique | 1 | 2020 | 157 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 224 | 0.160 |
Why?
| | Ocular Hypertension | 2 | 2011 | 61 | 0.150 |
Why?
| | Glaucoma, Open-Angle | 2 | 2011 | 94 | 0.150 |
Why?
| | Biopsy, Fine-Needle | 2 | 2008 | 65 | 0.150 |
Why?
| | Clinical Competence | 1 | 2022 | 882 | 0.130 |
Why?
| | Humans | 13 | 2022 | 114045 | 0.130 |
Why?
| | Pancreas | 2 | 2008 | 276 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 771 | 0.120 |
Why?
| | Community Health Services | 1 | 2016 | 212 | 0.120 |
Why?
| | Middle Aged | 6 | 2021 | 26605 | 0.110 |
Why?
| | Life Style | 1 | 2016 | 428 | 0.110 |
Why?
| | Aged | 5 | 2021 | 18969 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1175 | 0.110 |
Why?
| | Pandemics | 1 | 2021 | 1310 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4595 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2016 | 351 | 0.100 |
Why?
| | Family | 1 | 2016 | 589 | 0.100 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4402 | 0.090 |
Why?
| | Adult | 5 | 2021 | 30375 | 0.090 |
Why?
| | Primary Health Care | 2 | 2019 | 1502 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2016 | 489 | 0.080 |
Why?
| | Male | 6 | 2021 | 55396 | 0.080 |
Why?
| | Pilot Projects | 2 | 2016 | 1360 | 0.080 |
Why?
| | V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2008 | 10 | 0.080 |
Why?
| | Tissue Fixation | 1 | 2008 | 27 | 0.070 |
Why?
| | Female | 6 | 2021 | 59324 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 192 | 0.070 |
Why?
| | Gallstones | 1 | 2007 | 28 | 0.070 |
Why?
| | Lithotripsy | 1 | 2007 | 40 | 0.070 |
Why?
| | Cloprostenol | 1 | 2007 | 13 | 0.070 |
Why?
| | Timolol | 1 | 2007 | 14 | 0.070 |
Why?
| | Endosonography | 1 | 2008 | 132 | 0.070 |
Why?
| | Endoscopy, Digestive System | 1 | 2007 | 110 | 0.060 |
Why?
| | Cholelithiasis | 1 | 2006 | 31 | 0.060 |
Why?
| | Cholangiocarcinoma | 1 | 2006 | 38 | 0.060 |
Why?
| | Bile Duct Neoplasms | 1 | 2006 | 56 | 0.060 |
Why?
| | United States | 1 | 2021 | 12137 | 0.060 |
Why?
| | Retrospective Studies | 1 | 2022 | 12521 | 0.060 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1162 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2007 | 428 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1791 | 0.050 |
Why?
| | Biopsy | 1 | 2006 | 1024 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1331 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2007 | 4392 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2764 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2007 | 6306 | 0.040 |
Why?
| | Prospective Studies | 2 | 2007 | 6195 | 0.040 |
Why?
| | Colorado | 2 | 2019 | 4090 | 0.040 |
Why?
| | Community-Based Participatory Research | 1 | 2019 | 130 | 0.040 |
Why?
| | Biomarkers | 1 | 2008 | 3397 | 0.040 |
Why?
| | Behavior Control | 1 | 2016 | 14 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 575 | 0.030 |
Why?
| | Qualitative Research | 1 | 2019 | 919 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2016 | 735 | 0.030 |
Why?
| | Blood Pressure | 1 | 2016 | 1531 | 0.020 |
Why?
| | Intraocular Pressure | 1 | 2011 | 275 | 0.020 |
Why?
| | Body Mass Index | 1 | 2016 | 1957 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1381 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1836 | 0.020 |
Why?
| | Travoprost | 1 | 2007 | 13 | 0.020 |
Why?
| | Drug Combinations | 1 | 2007 | 286 | 0.020 |
Why?
| | Recurrence | 1 | 2007 | 925 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 926 | 0.010 |
Why?
| | Child | 1 | 2016 | 18401 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2007 | 9049 | 0.010 |
Why?
| | Animals | 1 | 2011 | 31565 | 0.010 |
Why?
| | Adolescent | 1 | 2007 | 17800 | 0.010 |
Why?
|
|
Awadallah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|